Mizuho Increases IQVIA (NYSE:IQV) Price Target to $230.00

IQVIA (NYSE:IQV) had its price target upped by stock analysts at Mizuho from $215.00 to $230.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Mizuho’s target price would indicate a potential upside of 10.51% from the stock’s current price.

Several other equities analysts have also issued reports on IQV. Weiss Ratings lowered shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Robert W. Baird increased their price target on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Evercore reiterated an “outperform” rating and issued a $185.00 price objective on shares of IQVIA in a research note on Wednesday, April 8th. HSBC restated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Finally, Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Trading Up 0.1%

Shares of IQV stock opened at $208.13 on Monday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA has a twelve month low of $154.50 and a twelve month high of $247.04. The firm has a market capitalization of $34.74 billion, a P/E ratio of 25.79, a P/E/G ratio of 1.78 and a beta of 1.20. The stock’s fifty day simple moving average is $181.62 and its 200 day simple moving average is $188.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the previous year, the firm earned $2.70 earnings per share. The firm’s quarterly revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts predict that IQVIA will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently made changes to their positions in the stock. Ameliora Wealth Management Ltd. bought a new stake in shares of IQVIA during the 4th quarter valued at $25,000. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter valued at $25,000. Ascentis Independent Advisors bought a new position in IQVIA in the 1st quarter valued at $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA during the 4th quarter valued at $27,000. Finally, Gilpin Wealth Management LLC bought a new position in shares of IQVIA in the fourth quarter worth $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.